ABBN.SW: $86.02 ▼ -0.08 (-0.09%)ASML.AS: $1,571.80 ▲ 11.00 (0.70%)ENR.DE: $160.78 ▼ -1.72 (-1.06%)GLEN.L: $536.40 ▲ 1.10 (0.21%)IFX.DE: $81.13 ▲ 0.57 (0.71%)NOKIA.HE: $12.11 ▲ 0.11 (0.92%)RIO.L: $7,303.00 ▲ 39.00 (0.54%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

TELA Bio, Inc.

TELA - NASDAQ

Identifiants & Marche

Ticker TELA
ISIN US8723811084
CIK 0001561921
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Medical - Devices

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.